These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 30794092

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
    Zhang L, Yu L, Xu Y, Qin P, Shen P, Liu K, Fei M, Wang H, Cao Y, Lu L, Gao W, Zhang Z.
    Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
    [Abstract] [Full Text] [Related]

  • 6. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
    Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, Wang D, Li W, Zhang Y, Feng J, Yang J, Zhang H, Jin C, Yang Y, Hu J, Wang Z, Jin Z, Su H, Wang H, Yang H, Fu W, Zhang M, Zhang X, Chen Y, Ke X, Liu L, Yu D, Chen G, Wang X, Jin J, Sun T, Du X, Cheng Y, Yi P, Zhao X, Ma C, Cheng J, Chai K, Luk A, Liu E, Zhang X.
    J Hematol Oncol; 2020 Apr 16; 13(1):38. PubMed ID: 32299513
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.
    Kim H, Hong E, Lee J, Hong S, Kim J, Cho M, Kim Y, Yoo T.
    BioDrugs; 2023 Jul 16; 37(4):569-581. PubMed ID: 37060541
    [Abstract] [Full Text] [Related]

  • 9. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML, Pesce A, Bès C, Seigelchifer M.
    BioDrugs; 2019 Jun 16; 33(3):307-319. PubMed ID: 30927214
    [Abstract] [Full Text] [Related]

  • 10. Analytical and functional similarity of biosimilar Elizaria® with eculizumab reference product.
    Gusarova V, Degterev M, Lyagoskin I, Simonov V, Smolov M, Taran S, Shukurov R.
    J Pharm Biomed Anal; 2022 Oct 25; 220():115004. PubMed ID: 35988306
    [Abstract] [Full Text] [Related]

  • 11. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J.
    MAbs; 2018 Oct 25; 10(4):678-691. PubMed ID: 29553864
    [Abstract] [Full Text] [Related]

  • 12. Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product.
    Seo N, Guan X, Wang T, Chung HSH, Wikström M, Padaki R, Kalenian K, Kuhns S, Matthies K, Crouse-Zeineddini J, Wong HY, Ng M, Foltz IN, Cao S, Liu J.
    Ophthalmol Ther; 2024 May 25; 13(5):1303-1320. PubMed ID: 38507189
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
    Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y.
    BMC Cancer; 2024 Jan 24; 24(1):124. PubMed ID: 38267866
    [Abstract] [Full Text] [Related]

  • 14. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology.
    Xie L, Zhang E, Xu Y, Gao W, Wang L, Xie MH, Qin P, Lu L, Li S, Shen P, Jiang W, Liu S.
    BioDrugs; 2020 Jun 24; 34(3):363-379. PubMed ID: 32072477
    [Abstract] [Full Text] [Related]

  • 15. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
    Saleem R, Cantin G, Wikström M, Bolton G, Kuhns S, McBride HJ, Liu J.
    Pharm Res; 2020 May 31; 37(6):114. PubMed ID: 32476063
    [Abstract] [Full Text] [Related]

  • 16. Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience.
    Deng W, Yang S, Yang C, Chen H, Huang G, Wu H, Chen J.
    J Oncol Pharm Pract; 2022 Jul 03; ():10781552221110470. PubMed ID: 35786067
    [Abstract] [Full Text] [Related]

  • 17. Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.
    Wang H, Wu L, Wang C, Xu J, Yin H, Guo H, Zheng L, Shao H, Chen G.
    ACS Pharmacol Transl Sci; 2021 Apr 09; 4(2):790-801. PubMed ID: 33860202
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE, Ómarsdóttir S, Roy N, Berger V, Michel C, Berti F.
    Ther Adv Chronic Dis; 2024 Apr 09; 15():20406223231223286. PubMed ID: 38250743
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.